MAIA
MAIA Biotechnology, Inc.
Biotechnology
Market Cap$55M
5Y Perf.-75.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MAIA vs CYCN
Revenue, margins, valuation, and 5-year total return — side by side.
CYCN
Cyclerion Therapeutics, Inc.
Biotechnology
Market Cap$13M
5Y Perf.-83.6%
MAIA vs CYCN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  MAIA |  CYCN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $55M | $13M |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-24M | $-5M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -337.4% |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $8.66B | $3M |
MAIA vs CYCN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MAIA
CYCN
| Stock | Jul 22 | Jun 26 | Return |
|---|---|---|---|
| MAIA Biotechnology,… (MAIA) | 100 | 24.7 | -75.3% |
| Cyclerion Therapeut… (CYCN) | 100 | 16.4 | -83.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MAIA vs CYCN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CYCN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. MAIA Biotechnology, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MAIA
MAIA Biotechnology, Inc.
The Growth Play
MAIA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 33.3%
- -67.9% 10Y total return vs CYCN's -98.8%
- 3.2% margin vs CYCN's -264.7%
Best for: growth exposure and long-term compounding
CYCN
Cyclerion Therapeutics, Inc.
The Income Pick
CYCN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.21
- Lower volatility, beta 1.21, current ratio 5.15x
- Beta 1.21, current ratio 5.15x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  CYCN | 3.7% revenue growth vs MAIA's -3.6% |
| Quality / Margins |  MAIA | 3.2% margin vs CYCN's -264.7% |
| Stability / Safety | CYCN | Beta 1.21 vs MAIA's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CYCN | -6.5% vs MAIA's -18.3% |
| Efficiency (ROA) | MAIA | -1.0% ROA vs CYCN's -55.1% |
MAIA vs CYCN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MAIA vs CYCN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMAIALAGGINGCYCN
CYCNCyclerion Therapeutic…
2leads
MAIAMAIA Biotechnology, I…
2leads
6 Total Categories
CATEGORYLEADERvs CYCNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MAIA1/1
Valuation MetricsMultiples, price ratios, and targets
CYCN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MAIA4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
CYCN4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MAIA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CYCN and MAIA operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$16M | -$7M |
| Net IncomeAfter-tax profit | -$24M | -$5M |
| Free Cash FlowCash after capex | -$20M | -$4M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -3.4% |
| Net MarginNet income ÷ Revenue | — | -2.6% |
| FCF MarginFCF ÷ Revenue | — | -180.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.5% | -35.7% |
MAIA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CYCN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| Market CapShares × price | $55M | $13M |
| Enterprise ValueMkt cap + debt − cash | -$8.6B | $10M |
| Trailing P/EPrice ÷ TTM EPS | -2.04x | -2.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.26x |
| Price / BookPrice ÷ Book value/share | 19.33x | 1.06x |
| Price / FCFMarket cap ÷ FCF | — | — |
CYCN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
MAIA leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
MAIA delivers a -4.0% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-62 for CYCN. On the Piotroski fundamental quality scale (0–9), MAIA scores 2/9 vs CYCN's 1/9, reflecting mixed financial health.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -4.0% | -62.1% |
| ROA (TTM)Return on assets | -1.0% | -55.1% |
| ROICReturn on invested capital | — | -65.1% |
| ROCEReturn on capital employed | -4.8% | -55.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$8.7B | -$3M |
| Cash & Equiv.Liquid assets | $8.7B | $3M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
MAIA leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
CYCN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MAIA five years ago would be worth $3,206 today (with dividends reinvested), compared to $464 for CYCN. Over the past 12 months, CYCN leads with a -6.5% total return vs MAIA's -18.3%. The 3-year compound annual growth rate (CAGR) favors CYCN at -11.5% vs MAIA's -15.3% — a key indicator of consistent wealth creation.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| YTD ReturnYear-to-date | -10.6% | +123.9% |
| 1-Year ReturnPast 12 months | -18.3% | -6.5% |
| 3-Year ReturnCumulative with dividends | -39.1% | -30.7% |
| 5-Year ReturnCumulative with dividends | -67.9% | -95.4% |
| 10-Year ReturnCumulative with dividends | -67.9% | -98.8% |
| CAGR (3Y)Annualised 3-year return | -15.3% | -11.5% |
CYCN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MAIA and CYCN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CYCN is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than MAIA's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MAIA currently trades 44.8% from its 52-week high vs CYCN's 35.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.21x |
| 52-Week HighHighest price in past year | $3.19 | $8.48 |
| 52-Week LowLowest price in past year | $0.87 | $1.03 |
| % of 52W HighCurrent price vs 52-week peak | +44.8% | +35.4% |
| RSI (14)Momentum oscillator 0–100 | 52.4 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 737K | 5.6M |
Evenly matched — MAIA and CYCN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MAIAMAIA Biotechnolog… | CYCNCyclerion Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MAIA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CYCN leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallMAIA Biotechnology, Inc. (MAIA)Leads 2 of 6 categories
Loading custom metrics...
MAIA vs CYCN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — MAIA or CYCN?
Over the past 5 years, MAIA Biotechnology, Inc.
(MAIA) delivered a total return of -67. 9%, compared to -95. 4% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: MAIA returned -67. 9% versus CYCN's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — MAIA or CYCN?
By beta (market sensitivity over 5 years), Cyclerion Therapeutics, Inc.
(CYCN) is the lower-risk stock at 1. 21β versus MAIA Biotechnology, Inc. 's 1. 71β — meaning MAIA is approximately 41% more volatile than CYCN relative to the S&P 500.
03Which is growing faster — MAIA or CYCN?
On earnings-per-share growth, the picture is similar: MAIA Biotechnology, Inc.
grew EPS 33. 3% year-over-year, compared to 9. 9% for Cyclerion Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — MAIA or CYCN?
MAIA Biotechnology, Inc.
(MAIA) is the more profitable company, earning 0. 0% net margin versus -170. 1% for Cyclerion Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MAIA leads at 0. 0% versus -239. 8% for CYCN. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MAIA or CYCN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MAIA or CYCN better for a retirement portfolio?
For long-horizon retirement investors, Cyclerion Therapeutics, Inc.
(CYCN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). MAIA Biotechnology, Inc. (MAIA) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYCN: -98. 8%, MAIA: -67. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MAIA and CYCN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.